Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

Fig. 2

PDC molecular subtypes and their drug responses. A Overall survival curve plot of the four molecular subtypes. P-values were acquired using the log-rank test. Hazard ratio (HRs) 95% confidence intervals (CIs) were determined using the Cox model. B Heatmap indicating average scores of activated pathways for each subtype identified using the limma test (P < 0.001). C Volcano plot to test drug sensitivity of all possible pairs of subtypes and drugs. The x-axis is the log-scale fold change (log2 FC) to subtype’s average AUC divided by the rest samples’ average AUC. The y-axis is the P-value performed by Wilcoxon rank-sum test. Drug–subtype pairs are labeled. D Heatmap of drug–subtype pairs determined from response sensitivity tests for each subtype (P ≤ 0.05 and log2 FC ≤ 0.2). Only 30 drugs to pass P-value cutoff for each subtype were denoted. The size of each circle showed log-scale P-values, and circle was colorized by log2 FC

Back to article page